Biblio

Found 20 results
Filters: Keyword is Rats and Author is Largent-Milnes, Tally M  [Clear All Filters]
2023
Martin LF, Cheng K, Washington SM, Denton M, Goel V, Khandekar M, Largent-Milnes TM, Patwardhan A, Ibrahim MM.  2023.  Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain.. J Pain. 24(3):509-529.
2022
Bartolo ND, Reid SE, Krishnan HS, Haseki A, Renganathan M, Largent-Milnes TM, Norwood BA, Loggia ML, Hooker JM.  2022.  Radiocaine: An Imaging Marker of Neuropathic Injury.. ACS Chem Neurosci. 13(24):3661-3667.
Vizcarra VS, Barber KR, Franca-Solomon G, Majuta L, Smith A, Langlais PR, Largent-Milnes TM, Vanderah TW, Riegel AC.  2022.  Targeting 5-HT receptors and Kv7 channels in PFC to attenuate chronic neuropathic pain in rats using a spared nerve injury model.. Neurosci Lett. 789:136864.
2020
Liktor-Busa E, Blawn KT, Kellohen KL, Wiese BM, Verkhovsky V, Wahl J, Vivek A, Palomino SM, Davis TP, Vanderah TW et al..  2020.  Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake.. PLoS One. 15(5):e0227463.
2019
Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, Falk T, Bartlett MJ, Doyle KP, Konhilas JP.  2019.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.. J Pharmacol Exp Ther. 369(1):9-25.
2018
Cottier KE, Galloway EA, Calabrese EC, Tome ME, Liktor-Busa E, Kim J, Davis TP, Vanderah TW, Largent-Milnes TM.  2018.  Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.. eNeuro. 5(4)
2016
Deekonda S, Cole J, Sunna S, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porecca F et al..  2016.  Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.. Bioorg Med Chem Lett. 26(1):222-7.
Ramos-Colon CN, Lee YSun, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM et al..  2016.  Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.. J Med Chem. 59(22):10291-10298.
2015
Deekonda S, Wugalter L, Rankin D, Largent-Milnes TM, Davis P, Wang Y, BassiriRad NM, Lai J, Kulkarni V, Vanderah TW et al..  2015.  Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.. Bioorg Med Chem Lett. 25(20):4683-8.
Deekonda S, Wugalter L, Kulkarni V, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porreca F et al..  2015.  Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.. Bioorg Med Chem. 23(18):6185-94.
Giri AKumar, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F et al..  2015.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.
2014
Hegarty DM, Hermes SM, Largent-Milnes TM, Aicher SA.  2014.  Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.. J Chem Neuroanat. 61-62:1-12.
Hofmann ME, Largent-Milnes TM, Fawley JA, Andresen MC.  2014.  External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.. J Neurophysiol. 112(11):2697-706.
Largent-Milnes TM, Hegarty DM, Aicher SA, Andresen MC.  2014.  Physiological temperatures drive glutamate release onto trigeminal superficial dorsal horn neurons.. J Neurophysiol. 111(11):2222-31.
2013
Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma S-W, Vanderah TW et al..  2013.  Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.. Bioorg Med Chem Lett. 23(17):4975-8.
2012
Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.  2012.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.
Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.  2012.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.. Eur J Pharmacol. 684(1-3):64-70.
2011
Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.
Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee Y-S, Ossipov MH, Hruby VJ et al..  2011.  Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.
2008
Largent-Milnes TM, Guo W, Wang H-Y, Burns LH, Vanderah TW.  2008.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.. J Pain. 9(8):700-13.